Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
Shares of Arcellx Inc. (ACLX) were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s (GILD) Kite as part of an expanded collaboration. Under terms of the investment, Gilead will buy 3.24 million Arcellx shares for $200 million, which will give Gilead a 13% stake in Arcellx, and extend Arcellx's cash runway into 2027. The investment represents a price of $61.68 for Arcellx's stock, which is 29.9% above Tuesday's closing price of $47.47. Kite has exercised its option to negotiate a license for Arcellx's multiple myeloma treatment. Arcellx's stock has run up 32.2% over the past three months through Tuesday and Gilead shares have lost 6.2%, while the S&P 500 has edged up 1.3%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-15-23 0623ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters